Search research articles
Contact Us
Filters
Showing results (251-260 of 269) with videos related to
Page
of 27
Sort By:
Nature Medicine
|
November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
Benjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Cancer Discovery
|
March 25, 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J Jordan, Hyunjae R Kim, Maria E Arcila, et al.
Cancer Discovery
|
June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 9, 2025
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer
Mihaela Aldea, Julia K Rotow, Maria Arcila, et al.
Journal of the National Cancer Institute
|
November 30, 2018
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers
Joshua K Sabari, Michael Offin, Dennis Stephens, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers
Lori J Wirth, Eric Sherman, Bruce Robinson, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
The New England Journal of Medicine
|
February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Sarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 269) with videos related to
Sort By:
Page
of 27
Nature Medicine
|
November 27, 2019
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
Benjamin H Durham, Estibaliz Lopez Rodrigo, Jennifer Picarsic, et al.
The Lancet. Oncology
|
December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Cancer Discovery
|
March 25, 2017
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J Jordan, Hyunjae R Kim, Maria E Arcila, et al.
Cancer Discovery
|
June 5, 2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 9, 2025
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer
Mihaela Aldea, Julia K Rotow, Maria Arcila, et al.
Journal of the National Cancer Institute
|
November 30, 2018
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers
Joshua K Sabari, Michael Offin, Dennis Stephens, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers
Lori J Wirth, Eric Sherman, Bruce Robinson, et al.
Cancer Discovery
|
April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
The New England Journal of Medicine
|
February 22, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Sarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Page
of 27